ABSTRACT
BACKGROUND:
ADAM10 (a disintegrin and metalloproteinase 10) has been demonstrated to act as the main physiological α-secretase. Enzymatic activity of the α-secretase on the one hand prevents the formation of toxic Aβ peptides and on the other hand promotes the secretion of a neurotrophic and neuroprotective amyloid precursor protein fragment (APPs-α) by cleaving the amyloid precursor protein within its Aβ sequence. Enhancement of ADAM10's gene expression may therefore present a valuable therapeutic approach for the treatment of Alzheimer's disease (AD), where Aβ peptides are severely involved in the pathogenesis.
OBJECTIVE:
In cell culture and in a transgenic mouse model of AD, retinoids led to increased ADAM10 expression and activity. We therefore endeavor to develop a clinical application of synthetic retinoids such as acitretin in AD.
METHODS:
The effect of synthetic retinoids on ADAM10 gene expression was analyzed by reporter gene assays in human neuroblastoma cell line SH-SY5Y. Penetrance of acitretin into the murine brain was analyzed by high-performance liquid chromatography. P-glycoprotein (P-gp) double-knockout mice with a deficiency in both isoforms, mdr1a and 1b, were used to analyze a possible role of P-gp-dependent efflux on acitretin distribution.
RESULTS:
Acitretin and tamibarotene are both potent activators of ADAM10 promoter activity. Acitretin crosses the murine blood-brain barrier and its level in the mouse brain is not reduced by P-gp.
CONCLUSION:
Synthetic retinoids and especially acitretin seem to be ideal candidates to establish an ADAM10-based AD treatment, and therefore have already entered first clinical trials.
Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein
Riferimento:
Neurodegener Dis. 2012;10(1-4):224-8.
Autori:
Holthoewer D, Endres K, Schuck F, Hiemke C, Schmitt U, Fahrenholz F.
Fonte:
Neurodegener Dis. 2012;10(1-4):224-8.
Anno:
2012
Azione:
Retinoidi sintetici e soprattutto acitretina sembrano essere i candidati ideali per stabilire un ADAM10 (un disintegrina e metalloproteinasi 10) base del trattamento della malattia di Alzheimer (AD).
Target:
Acitetrina/malattia di Alzheimer
Sostanze:
